Ligand Pharma (LGND) Tops Q3 EPS by 40c; offers guidance

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.02, $0.40 better than the analyst estimate of $0.62. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $27.22 million.

GUIDANCE:

Ligand Pharma sees FY2023 EPS of $5.25-$5.40, versus the consensus of $5.04. Ligand Pharma sees FY2023 revenue of $126-129 million, versus the consensus of $126.5 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings